证券研究报告·行业跟踪周报·医药生物 医药生物行业跟踪周报 2026 版基药目录调整在即，利好拟纳入目录 的中药标的 增持（维持） [Table_Tag] [Table_Summary] 投资要点 ◼ 具体思路:看好的子行业排序分别为:创新药>科研服务>CXO>中药>医疗器械>药店 等。具体标的思路：从中药基药角度，建议关注佐力药业、方盛制药、盘龙药业等。 从 CXO、上游科研服务角度，建议关注药明康德、皓元医药、奥浦迈、百奥赛图、 百普赛斯、纳微科技等。从 PD1 PLUS 角度，建议关注三生制药、康方生物、信达生 物、泽璟制药等。从 ADC 角度，建议关注映恩生物、科伦博泰、百利天恒等。从小 核酸角度，建议关注前沿生物、福元医药、悦康药业等。从自免角度，建议关注康 诺亚、益方生物-U、一品红等。从创新药龙头角度，建议关注百济神州、恒瑞医药 等。从医疗器械角度，建议关注联影医疗、鱼跃医疗等。从 AI 制药角度，建议关注 晶泰控股、英矽智能等。从 GLP1 角度，建议关注联邦制药、博瑞医药、众生药业 等。 ◼ 风险提示：药品或耗材降价超预期；医保政策风险等；产品销售及研发进度不及预 期。 2026 年 03 ...

2026 年 3 月 1 日 行情回顾：上周 A 股医药生物（申万，下同）指数上涨 0.50%，跑输沪深 300 指数 0.58pp，跑输创业板综指 1.82pp，在 31 个子行业中排名第 25。港股恒生 医疗健康指数上周收跌 6.07%，跑输恒生国企指数 4.96pp。 研发进展：上周，康哲药业的 CMS-D008 注射液、康辰药业的 KC1036 片的临 床申请新进承办；海思科的 HSK46575 片、百利天恒的注射用伦康依隆妥单抗 和注射用 BL-M11D1 的 IND 申请新进承办；恒瑞医药的 SHR-1905 注射液以及 SHR-1819 注射液申请临床。 上周，诺诚健华的 ICP-538 以及华润双鹤的 DC6001 正在进行一期临床；复宏 汉霖的 HLX43 和天境生物的普那利单抗进行二期临床；石药集团的 SYH2053 和 SYS6010 进行三期临床；禾元生物的重组人白蛋白（水稻）进行四期临床。 本周观点：坚定看好医药板块回暖，重申投资临床价值三段论 从临床价值三段论看投资主线：1）"0→1"技术突破：创新药领域，高端前沿 创新靶点，正在肿瘤、减重、自免等领域重塑药企研发格局；创新器械领域 ...

Core Viewpoint - The A-share market has shown active trading with significant focus on sectors like chemicals and non-ferrous metals, driven by price increases and strong performance in ETFs related to these sectors [1][2]. Group 1: Market Performance - The A-share market closed February with the Shanghai Composite Index achieving three consecutive monthly gains, with daily trading volumes exceeding 1 trillion yuan becoming a norm [1]. - On February 27, the total trading volume in the Shanghai, Shenzhen, and Beijing markets reached 2.51 trillion yuan, slightly down by 504 billion yuan from the previous day [1]. - Over 3,200 stocks in the market saw gains, with notable performances in small metals and rare earths, leading to a surge in stocks like Hunan Gold [1]. Group 2: Sector Highlights - The non-ferrous metals sector continued to perform strongly, with the non-ferrous ETF (159876) reaching a peak increase of 3.82% and closing up 3.74% on the day [4]. - The chemical sector benefited from rising prices, with the chemical ETF (516020) achieving four consecutive daily gains, marking its highest point since January 2022 [1][4]. - The AI sector is gaining traction, with domestic AI usage surpassing that of the US, benefiting the domestic AI industry chain, as reflected in the performance of the innovation-focused AI ETF (589520) [1]. Group 3: ETF Performance - The electric power ETF (159146) saw a significant increase of 2.64%, reaching a new high since its listing, driven by the rising demand for electricity due to AI development [2][10]. - The largest medical ETF (512170) in the market rose by 1.14%, recovering its annual line, with a net inflow of over 1.9 billion yuan in the previous three days [14][16]. - The electric power sector is viewed as a defensive investment amid the AI boom, with the electric power ETF focusing on various energy sources including thermal, hydro, wind, nuclear, and solar power [12]. Group 4: Future Outlook - Analysts suggest that the non-ferrous metals sector still has upward momentum, supported by supply disruptions and high demand, with a focus on precious, industrial, battery, and strategic metals [7]. - The medical sector is expected to recover, with growth opportunities arising from performance recovery, overseas expansion, brain-computer interfaces, and AI in healthcare [16][18].

Investment Rating - The report maintains a "Market Perform" rating for the pharmaceutical and biotechnology industry, indicating that the industry index is expected to perform within ±10% of the market index over the next six months [3][26]. Core Insights - The SW pharmaceutical and biotechnology industry underperformed the CSI 300 index, declining by 0.95% from February 13 to February 26, 2026, which is approximately 1.1 percentage points lower than the index [11]. - Most sub-sectors within the industry recorded positive returns during the same period, with "Other Biological Products" and "Hospitals" leading with increases of 2.42% and 1.80%, respectively. Conversely, "Medical R&D Outsourcing" and "Offline Pharmacies" saw declines of 3.80% and 0.65% [12][24]. - Approximately 52% of stocks in the industry reported positive returns, with the highest gain being 14.44% for Erkang Pharmaceutical, while the largest decline was 13.28% for Zexing Pharmaceutical-U [13][16]. - The overall industry valuation remained stable, with a Price-to-Earnings (PE) ratio of approximately 51.16 times as of February 26, 2026, which is 3.82 times higher than the CSI 300 index [18][26]. Summary by Sections 1. Market Review - The SW pharmaceutical and biotechnology industry underperformed the CSI 300 index, with a decline of 0.95% from February 13 to February 26, 2026 [11]. - Most sub-sectors recorded positive returns, with "Other Biological Products" and "Hospitals" leading the gains [12]. - About 52% of stocks in the industry achieved positive returns, with notable performances from Erkang Pharmaceutical and Zexing Pharmaceutical-U [13][16]. - The industry valuation showed little change, with a PE ratio of 51.16 times [18]. 2. Industry News - The Zhejiang Medical Insurance Bureau announced a training session for the centralized procurement of two types of medical consumables, which includes cardiac pacemakers and peripheral vascular intervention micro-catheters [24]. - The average price reduction for cardiac pacemakers was reported at 43.09%, with the highest reduction reaching 76.13% for implantable pacemakers [24]. 3. Company Announcements - Sinovac Biotech announced the approval of a clinical trial for its innovative drug GB19 injection, which targets BDCA2 [25]. 4. Industry Outlook - The report suggests a focus on investment opportunities in the brain-computer interface sector, which is highlighted in the 14th Five-Year Plan [26]. - Recommended stocks for attention include leading companies in medical devices, pharmaceutical retail, aesthetic medicine, scientific services, and traditional Chinese medicine [28].

2025 年医疗大模型品牌推荐 2025 年医疗大模型品牌推荐 海量知识深度整合，智能生成革新医疗范式 | 一、市场背景 | 2 | | --- | --- | | 1.1 摘要 | 2 | | 1.2 医疗大模型定义 | 2 | | 1.3 市场演变 | 2 | | 二、市场现状 | 3 | | 2.1 市场规模 | 3 | | 2.2 市场供需 | 3 | | 三、市场竞争 | 3 | | 3.1 市场评估维度 | 3 | | 3.2 市场竞争格局 | 4 | | 3.3 十大品牌推荐 | 4 | | 四、发展趋势 | 5 | | 4.1 底层算法与数据质量升级 | 6 | | 4.2 应用形态与部署模式多元化 | 6 | | 4.3 商业模式与生态构建平台化 | 6 | 自 2019 年医疗大模型诞生以来，其发展经历了从通用模型的基础能力迁移，到专业医 疗知识的深度对齐，再到多模态与临床工作流融合的快速演进。早期模型如 BioBERT、ClinicalBERT 通过生物医学语料预训练夯实了基础能力；随后 Med-PaLM、 HuaTuoGPT 等模型通过指令微调与知识增强，在医学问答、报告生成等任务中展 ...

与往年新春赴沪的对接交流有所不同，本次交流合作周将"科创融合"置于核心位置。 这一转变源于2025年底中央经济工作会议明确"建设北京（京津冀）、上海（长三角）、粤港澳大湾区国际科技创新中心"的战 略新动向。 对此，常州市委书记王剑锋在2月26日的常州—上海经贸交流和创新合作活动周新春交流会上明确，"抢抓上海国际科创中心扩 围至长三角的重大机遇"。 扩围的核心要义，在于让创新资源在区域内高效流动，让科研成果真正转化为产业动能。上海国际科创中心扩围至长三角，正 为沪常合作打开全新的想象空间。 沪常共链 21世纪经济报道记者孙燕 上海报道 马年伊始，常州赴上海开展为期一周的经贸交流和创新合作活动，这也是常州连续第20年举办上海经贸活动周。 科创融合 随着上海国际科创中心建设正式从市域扩围至长三角全域，常州的坐标正在被重新定义。 目前在上海大都市圈中，常州不仅是产业创新绿色发展空间保障的一环，也是太湖周边地区科创空间布局的重要节点：《上海 大都市圈国土空间规划（2025—2035年）》（征求意见稿）提出，上海、苏州、无锡、常州、湖州、嘉兴、宣城着眼大都市圈 西翼太湖周边地区，发挥上海（长三角）国际科技创新中心的引领作 ...

A股2月收官！沪指月线斩获3连阳，春节后市场交投持续活跃，"日成交超万亿"已成常态。从板块来 看，热点聚焦度显著提升，涨价题材大放异彩，化工、有色金属表现突出。 全球AI发展驱动电力需求激增，叠加"HALO交易"加持，电力ETF（159146）场内再涨2.64%连创上市 新高，基金经理曹旭辰指出，伴随AI发展，软件等轻资产公司易被取代，而能源、电力等实物资产具 备不可或缺性，属于AI热潮下的防御性投资。此外，脑机接口赛道升温，AI大科技浪潮下，医药行业 有望释放新的成长逻辑，全市场规模最大医疗ETF（512170）盘中上探1.14%，此前3日获资金净申购逾 1.9亿元。 | 序号 代码 | | 名称 | 涨跌幅 ▼ | | --- | --- | --- | --- | | 1 11 | 159876 | 有色ETF华宝 | 3.74% | | 2 三 | 159146 | 电力ETF华宝 | 2.64% | | 3 | 159275 | 农牧渔ETF | 2.24% | | 4 | 516700 | 大数据ETF华宝 | 2.05% | | 5 | 589520 | 科创人工智能ETF华宇 | 2.03% ...

2月27日，A股医疗板块全天飘红，全市场规模最大医疗ETF（512170）盘中上探1.14%，成功收复年 线，成交3.84亿元。场内持续溢价交易，显示买盘态度积极，此前3日512170累获逾1.9亿元净申购。 | 分时 多日 1分 5分 * | | | | F9 盘前盘后 徽加 九特 画线 工具 @ (2 )> | | | | | 顾疗ETF O | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | | 512170医疗ETF] 15:00 价 0.355 通联 0.003(0.85%) 均价 0.354 1 512170(医疗器价交易 | | | | 0.354 +0.002 +0.57% | | 512170 | | | | 0.355 | | A NAT THE | | A CAL WHEY YOUNG WALL OLT OF O | | | SSE CNY 15:00:16 图布 查看L2全覆 | | 通政人员干 | | | | | | | | | | 净值走势 | | 华宝中让医疗L ...

10% 医药生物 沪深300 -5% 0% 5% 10% 医药生物 沪深300 标配（维持） 医药生物行业双周报（2026/2/13-2026/2/26） 静待板块回暖 投资要点： 本报告的风险等级为中高风险。 本报告的信息均来自已公开信息，关于信息的准确性与完整性，建议投资者谨慎判断，据此入市，风险自担。 请务必阅读末页声明。 行 业 研 -35% -35% -30% -20% 0% 20% 医药生物 沪深300 -15% -10% -5% 0% 5% 10% 医药生物 沪深300 分析师：谢雄雄 SAC 执业证书编号： S0340523110002 电话：0769-22110925 邮箱： -40% 22-03 22-05 22-07 22-09 22-11 23-01 23-03 -30% -25% -20% xiexiongxiong@dgzq.com.cn -35% 资料来源：iFind，东莞证券研究所 相关报告 -30% -25% -20% -15% -10% 5% -25% -20% -15% -10% -5% 0% -35% 2026 年 2 月 27 日 医药生物（申万）指数走势 证 券 研 ...

Group 1: Company Performance - BeiGene reported a total revenue of 38.205 billion yuan for 2025, a 40.4% increase from 27.214 billion yuan in the previous year, with a net profit of 1.422 billion yuan compared to a loss of 4.978 billion yuan in the prior year [1] - United Imaging achieved a total revenue of 13.821 billion yuan in 2025, reflecting a year-on-year growth of 34.18%, with a net profit of 1.888 billion yuan, up 49.6% [2] - Innovent Biologics expects a profit increase of 80%-94% to between 1.3 billion and 1.4 billion yuan for 2025, with total revenue projected at approximately 7.7-7.8 billion yuan, a growth of 16.0%-17.6% [3] - Zai Lab reported a total revenue of $460 million for 2025, a 15% increase, with significant growth in product sales driven by the performance of its drugs [4] Group 2: Product and Market Developments - BeiGene's global sales of its product, Baiyueze®, reached 28.067 billion yuan, marking a 48.8% year-on-year increase, establishing its leadership in the BTK inhibitor market [1] - United Imaging's growth was attributed to the continuous launch of innovative products and enhanced market recognition of high-end products [2] - Zai Lab's revenue growth was primarily due to increased sales of its products, including significant gains in the fourth quarter [4] - Innovent Biologics noted that revenue growth was driven by increased income from innovative drugs and licensing agreements [3] Group 3: Strategic Moves and Collaborations - Hengrui Medicine signed an exclusive licensing and equity cooperation agreement with Solstice Oncology, with a total transaction value exceeding $1.2 billion [6] - Aibo Medical plans to acquire a 68.31% stake in Demei Medical for 683 million yuan, aiming to expand into the sports medicine sector [7] - The target company in the acquisition has 276 patented technologies and is recognized as a leading enterprise in the domestic sports medicine field [8]